Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality
Drug Research · 2024-01 · 74 (01) · 18-23
DOI: 10.1055/a-2185-4916 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Research, online erschienen am 22.12.2023. Verfasst von Raja Shekhar Nunavath und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, India. Hauptthemen laut MEDLINE: Drug Industry. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
The pharmaceutical industry has embraced the quality-by-design (QbD) approach as a promising development, formulation and manufacturing strategy. QbD provides a systematic and science-based framework for designing and producing high-quality products, with a particular focus on identifying, assessing and controlling risks throughout the development process. This review aims to assess the benefits of implementing QbD in pharmaceutical processes, evaluate its impact on regulatory compliance and explore its potential to enhance drug product quality. The primary objective of this review is to evaluate the influence of QbD on pharmaceutical development and manufacturing processes. It also seeks to examine the regulatory requirements associated with the implementation of QbD and highlight the advantages of this approach in terms of product quality and cost-effectiveness. Additionally, the review aims to explore the potential of QbD in improving the safety and efficacy of drug products. The QbD approach holds tremendous potential to revolutionize the pharmaceutical industry by optimizing drug development & manufacturing processes, reducing costs and enhancing product quality and consistency. However, implementing QbD requires a comprehensive understanding of the underlying science, as well as strict adherence to regulatory requirements in drug development and manufacturing. In conclusion, by embracing the QbD approach, the pharmaceutical industry can ensure the production of safe, effective and regulation-compliant products while simultaneously improving process efficiency. This strategic shift toward QbD represents a pivotal step in advancing pharmaceutical research and manufacturing capabilities, ultimately benefiting both the industry and more importantly, patients worldwide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, India.
- Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, India.
- Department of Pharmaceutical Chemistry, Shri Aurobindo College of Pharmacy, Indore, Madhya Pradesh, India.
- Department of Pharmaceutics, College of Pharmacy, JSS Academy of Technical Education, Noida, Uttar Pradesh, India.
- Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Sri Shivarathreeshwara Nagar, Mysore, KA, India.
- Department of Pharmaceutical Analysis, College of Pharmacy, JSS Academy of Technical Education, Noida, Uttar Pradesh, India.
Zitieren
APA
Nunavath, R. S., Singh, M. T., Jain, A., Chakma, M., Arivuselvam, R., & Azeeze, M. S. T. A. (2024). Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality. Drug Research, 74(01), 18-23. https://doi.org/10.1055/a-2185-4916
Vancouver
Nunavath RS, Singh MT, Jain A, Chakma M, Arivuselvam R, Azeeze MSTA. Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality. Drug Research. 2024;74(01):18-23. doi:10.1055/a-2185-4916
BibTeX
@article{Nunavath2024,
author = {Nunavath, Raja Shekhar and Singh, Madhu Tanya and Jain, Anubha and Chakma, Marjita and Arivuselvam, Rajaguru and Azeeze, Mohamed Sheik Tharik Abdul},
title = {Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality},
journal = {Drug Research},
year = {2024},
volume = {74},
number = {01},
pages = {18--23},
doi = {10.1055/a-2185-4916}
}
EUVIMED